Showing results (921-930 of 945) with videos related to
Sort By:
Pageof 95
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activityCameron J Smith, Amjad Ali, James M Balkovec, et al.Human Molecular Genetics|October 29, 2013
CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1Elliott Rees, James T R Walters, Kimberly D Chambert, et al.Hemasphere|May 8, 2023
NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple MyelomaChristie P M Verkleij, Kristine A Frerichs, Marloes E C Broekmans, et al.Cell Metabolism|November 22, 2016
Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained ImmunityRob J W Arts, Boris Novakovic, Rob Ter Horst, et al.Molecular Psychiatry|February 19, 2009
Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphismsP A Holmans, B Riley, A E Pulver, et al.Nature Communications|August 31, 2018
Nrf2 negatively regulates STING indicating a link between antiviral sensing and metabolic reprogrammingDavid Olagnier, Aske M Brandtoft, Camilla Gunderstofte, et al.Nature Immunology|July 20, 2017
A guiding map for inflammationMihai G Netea, Frances Balkwill, Michel Chonchol, et al.Molecular Psychiatry|November 13, 2013
Evidence that duplications of 22q11.2 protect against schizophreniaE Rees, G Kirov, A Sanders, et al.Science (New York, N.Y.)|September 27, 2014
mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunityShih-Chin Cheng, Jessica Quintin, Robert A Cramer, et al.Schizophrenia Research|October 15, 2022
Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortiumSophie E Smart, Deborah Agbedjro, Antonio F Pardiñas, et al.Pageof 95